|
시장보고서
상품코드
2078731
만성 외상성 뇌병변(CTE) 시장 규모, 점유율 및 성장 분석 : 제품 유형별, 투여 경로별, 개발 단계별, 작용기전별, 적용 대상별, 지역별 - 업계 예측(2026-2033년)Chronic Traumatic Encephalopathy Market Size, Share, and Growth Analysis, By Drug Product Type, By Route of Administration, By Stage of Development, By Mechanism of Action, By Application Target, By Region - Industry Forecast 2026-2033 |
||||||
세계의 만성 외상성 뇌병변(CTE) 시장 규모는 2024년에 6억 1,240만 달러로 평가되었고, 2025년 6억 4,363만 달러에서 2033년까지 9억 5,821만 달러로 성장하여 예측 기간(2026-2033년)에 CAGR 5.1%를 기록할 전망입니다.
세계 만성 외상성 뇌병증(CTE) 시장은 반복되는 두부 외상으로 인한 신경퇴행성 질환 위험에 대한 인식이 높아지는 것을 배경으로, 눈부신 성장을 이루고 있습니다. 이러한 인식의 확산에 따라 보험사, 의료 서비스 제공업체, 정책 입안자들은 조기 발견 노력을 우선시하게 되었으며, 운동선수, 군 관계자, 고령자를 대상으로 한 진단, 치료, 조사 및 사후 분석 서비스가 추진되고 있습니다. 시장의 범위는 학술적인 병리 검사실에 그치지 않고, 혁신적인 검사 및 치료 솔루션 분야로 확대되고 있습니다. 혈액 검사에 중점을 둔 스타트업에 대한 벤처 캐피털의 투자가 증가하는 한편, 대형 제약사들은 질환 수정 치료제 개발에 협력하고 있습니다. 상환 프로그램 및 규제 체계의 확충에 더해, 접촉 스포츠에서의 뇌진탕 검사 의무화가 새로운 수익 기회를 창출하고 있으며, 궁극적으로는 전 세계적으로 첨단 영상 진단 및 바이오마커 솔루션에 대한 수요를 높이고 있습니다.
세계 만성 외상성 뇌병증(CTE) 시장의 성장 요인
세계 만성 외상성 뇌병증(CTE) 시장의 성장은 환자 모니터링 및 치료의 강화, 그리고 이 질환의 조기 발견 기법의 발전 등 여러 요인에 의해 주도되고 있습니다. 일반 시민들의 인식 제고와 진단 기술의 발전도 이러한 추세에 기여하고 있습니다. 또한, 의료 종사자 및 스포츠 단체를 중심으로 선별 검사 프로토콜 도입이 확대됨에 따라, 혁신적인 진단 도구 및 관련 서비스에 대한 수요가 증가하고 있습니다. 이처럼 높아지는 관심은 조사에 대한 투자를 촉진하고, 질환 관리 개선을 목표로 한 협력을 도모하며, 임상 현장과 스포츠 환경에서 새로운 진단 및 치료 솔루션의 보급을 통해 시장 성장을 위한 큰 기회를 제공합니다.
세계 만성 외상성 뇌병증(CTE) 시장의 제약 요인
세계 만성 외상성 뇌병증(CTE) 시장은 질병의 경과를 변화시킬 수 있는 치료법이 존재하지 않아, 임상 관리가 대증요법에 국한된다는 중대한 제약에 직면해 있습니다. 이러한 상황으로 인해 진단법의 발전이 가져다주는 이점이 과소평가되고 있으며, 특히 선택지가 제한적인 경우 의료 서비스 제공업체들이 새로운 검사 기법의 도입에 소극적인 태도를 보이게 되고 있습니다. 그 결과, 이러한 상황은 제품 개발에 대한 투자 감소로 이어질 가능성이 있으며, 게다가 새로운 치료법 도입을 위한 명확한 로드맵이 부재한 보험 급여 체계가 이러한 상황을 더욱 악화시키고 있습니다. 시장은 수용도가 높아짐에 따라 성장이 기대되지만, 효과적인 치료법 선택지가 여전히 부족한 점은 여전히 중대한 과제로 남아 있습니다.
세계 만성 외상성 뇌병증(CTE) 시장 동향
세계 만성 외상성 뇌병증(CTE) 시장은 신경 진단 및 조기 발견 조사 기법의 혁신에 힘입어 큰 변화를 겪고 있습니다. 첨단 신경 영상 기술과 체액 바이오마커 플랫폼에 대한 투자가 증가함에 따라, 임상의들은 돌이킬 수 없는 손상이 발생하기 전, 더 초기 단계에서 CTE 병변을 파악할 수 있게 되었습니다. 고해상도 MRI와 새로운 혈액 검사법에 인공지능(AI)을 접목함으로써 진단 과정이 효율화되고, 환자에 대한 예방적 관리가 강화되고 있습니다. 이러한 추세는 영상 진단 기업, 학술 기관, 보험사 간의 협력을 촉진하고 있으며, 그 결과 조기 발견이 신경학 헬스케어 생태계의 핵심 과제로 부상하고 있습니다. 또한, 규제 측면에서의 인식이 확산됨에 따라 보험 급여가 용이해져, 임상 현장에서의 도입이 확대될 길이 열리고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 만성 외상성 뇌병변(CTE) 시장 규모 : 의약품 제품 유형별
세계의 만성 외상성 뇌병변(CTE) 시장 규모 : 투여 경로별
세계의 만성 외상성 뇌병변(CTE) 시장 규모 : 개발 단계별
세계의 만성 외상성 뇌병변(CTE) 시장 규모 : 작용기전별
세계의 만성 외상성 뇌병변(CTE) 시장 규모 : 적용 대상별
세계의 만성 외상성 뇌병변(CTE) 시장 규모 : 제공 유형별
세계의 만성 외상성 뇌병변(CTE) 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.07.09Global Chronic Traumatic Encephalopathy Market size was valued at USD 612.4 Million in 2024 and is poised to grow from USD 643.63 Million in 2025 to USD 958.21 Million by 2033, growing at a CAGR of 5.1% during the forecast period (2026-2033).
The Global Chronic Traumatic Encephalopathy (CTE) market is experiencing significant growth driven by increasing awareness of the neurodegenerative risks associated with repeated head trauma. This awareness has led insurers, healthcare providers, and policymakers to prioritize early detection efforts, advancing diagnostic, therapeutic, research, and post-mortem analysis services for athletes, military personnel, and the aging population. The market's scope has expanded beyond academic pathology labs into the realm of innovative testing and treatment solutions. Venture capital is increasingly flowing into startups focused on blood-based assays while major pharmaceutical companies collaborate on disease-modifying drugs. Rising reimbursement programs and regulatory frameworks, along with mandatory concussion testing in contact sports, are creating new revenue opportunities, ultimately heightening demand for advanced imaging and biomarker solutions globally.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chronic Traumatic Encephalopathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Chronic Traumatic Encephalopathy Market Segments Analysis
Global chronic traumatic encephalopathy market is segmented by drug product type, route of administration, stage of development, mechanism of action, application target, offering type and region. Based on drug product type, the market is segmented into Small Molecule Drugs and Biologic Drugs. Based on route of administration, the market is segmented into Oral Formulations and Injectable Formulations. Based on stage of development, the market is segmented into Preclinical Stage, Phase I Trials, Phase II Trials and Phase III Trials. Based on mechanism of action, the market is segmented into Neuroprotective Agents and Anti-inflammatory Therapeutics. Based on application target, the market is segmented into Professional Athletes, Military Veterans and Others. Based on offering type, the market is segmented into Therapeutics and Supplements, Diagnostic Imaging Equipment, Biomarker Assay Kits and Clinical Care Services. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Chronic Traumatic Encephalopathy Market
The expansion of the Global Chronic Traumatic Encephalopathy market is being propelled by several factors, including enhanced monitoring and treatment of patients, as well as advancements in early detection methods for the disease. Growing public awareness and improvements in diagnostic technologies are contributing to this trend. Additionally, the rising implementation of screening protocols by healthcare professionals and sports organizations is boosting the demand for innovative diagnostic tools and associated services. This heightened visibility encourages investments in research and fosters collaborations aimed at improving disease management, presenting significant opportunities for market growth through the broader adoption of emerging diagnostic and care solutions in clinical and athletic environments.
Restraints in the Global Chronic Traumatic Encephalopathy Market
The global chronic traumatic encephalopathy market faces significant restraints due to the absence of disease-modifying treatments, which limits clinical management to symptomatic approaches. This scenario diminishes the perceived benefits of advancements in diagnostic methods, resulting in a reluctance among healthcare providers to embrace new testing modalities, particularly when these options are scarce. Consequently, this situation may lead to a reduction in investment for product development, compounded by reimbursement frameworks that lack a clear pathway for introducing new interventions. Although the market is likely to see growth driven by increased acceptance, the ongoing lack of effective treatment alternatives remains a critical challenge.
Market Trends of the Global Chronic Traumatic Encephalopathy Market
The Global Chronic Traumatic Encephalopathy (CTE) market is experiencing a significant shift driven by innovations in neurodiagnostics and early detection methodologies. With increased investments in advanced neuroimaging technologies and fluid biomarker platforms, clinicians can now identify CTE pathology at earlier stages, prior to irreversible damage. The incorporation of artificial intelligence with high-resolution MRI and novel blood assays is streamlining diagnostic processes, enhancing proactive patient management. This trend is fostering collaborations among imaging companies, academic institutions, and payers, thereby making early detection a focal point within neurology healthcare ecosystems. Additionally, evolving regulatory recognition is paving the way for easier reimbursement and expanding clinical adoption.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Chronic Traumatic Encephalopathy Market Size by Drug Product Type & CAGR (2026-2033)
- Market Overview
- Small Molecule Drugs
- Biologic Drugs
Global Chronic Traumatic Encephalopathy Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral Formulations
- Injectable Formulations
Global Chronic Traumatic Encephalopathy Market Size by Stage of Development & CAGR (2026-2033)
- Market Overview
- Preclinical Stage
- Phase I Trials
- Phase II Trials
- Phase III Trials
Global Chronic Traumatic Encephalopathy Market Size by Mechanism of Action & CAGR (2026-2033)
- Market Overview
- Neuroprotective Agents
- Anti-inflammatory Therapeutics
Global Chronic Traumatic Encephalopathy Market Size by Application Target & CAGR (2026-2033)
- Market Overview
- Professional Athletes
- American Football Players
- Hockey and Rugby Players
- Military Veterans
- Others
Global Chronic Traumatic Encephalopathy Market Size by Offering Type & CAGR (2026-2033)
- Market Overview
- Therapeutics and Supplements
- Diagnostic Imaging Equipment
- Biomarker Assay Kits
- Clinical Care Services
Global Chronic Traumatic Encephalopathy Market Size & CAGR (2026-2033)
- North America (Drug Product Type, Route of Administration, Stage of Development, Mechanism of Action, Application Target, Offering Type)
- US
- Canada
- Europe (Drug Product Type, Route of Administration, Stage of Development, Mechanism of Action, Application Target, Offering Type)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Product Type, Route of Administration, Stage of Development, Mechanism of Action, Application Target, Offering Type)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Product Type, Route of Administration, Stage of Development, Mechanism of Action, Application Target, Offering Type)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Product Type, Route of Administration, Stage of Development, Mechanism of Action, Application Target, Offering Type)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eisai Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens Healthineers AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GE HealthCare Technologies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Koninklijke Philips N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Avid Radiopharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- TauRx Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AC Immune SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Neurimmune AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Prothena Corporation plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Annovis Bio Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cassava Sciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Denali Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biohaven Pharmaceutical Holding Company Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
